An interventional study of Leadless Micra AV Transcatheter Pacing System and Transvenous Azure XT DR dual chamber pacemaker in AV Block, sponsored by University of Aarhus. Active, not recruiting at 2 sites in Denmark. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by University of Aarhus · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Atrioventricular Block with a site in Denmark — 1 open to participants now, 2 under way, none of them phase 3. Atrioventricular Block · Denmark.
Among the 11 studies in Atrioventricular Block with a site in Denmark, this one is the only one that started in 2023, is one of 4 with no phase, and was the 11th registered.
118 studies on the registry are indexed under Atrioventricular Block; 44 are open to participants now.
Browse Atrioventricular Block studies →1 of the 11 studies in Atrioventricular Block with a site in Denmark is open now. Recruiting first, the newest first:
Steen Hvitfeldt Poulsen · Sites in Denmark
Ages 65+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 29 Atrioventricular Block studies recruiting now, 21 (72%) set no upper age limit and 4 (14%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 75 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 80 is below the median of 130 across 79 interventional studies indexed under Atrioventricular Block.
Median enrollment 80 across the 7 interventional studies, 713 across the 4 observational. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 11 have an industry lead sponsor. The 8 most frequent:
University of Aarhus is the lead sponsor of 1,303 studies on the registry; 190 are open to participants now.
University of Aarhus has 2 studies filed under Atrioventricular Block — fewer than ten, so there is no comparison to draw.
1 of the studies in Atrioventricular Block with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05856799University of AarhusDanish Randomized Trial on Leadless vs Transvenous Pacing | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Atrioventricular Block with a site in Denmark, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the quality of life, patient acceptance and exercise capacity with leadless compared to transvenous pacing in elderly patients with new-onset high-grade atrioventricular block. Consecutive patients with high-grade atrioventricular black and preserved sinus node function with indication for permanent pacemaker implantation according to the latest european guidelines, are included in a prospective, partly patient and accessor blinded and partly open label, 1:1 randomized combined parallel and cross-over trial to implantation with 1) a Micra AV Transcathter Pacing System or 2) an Azure XT DR dual chamber pacemaker.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Implantation with a leadless pacemaker
Device: Leadless Micra AV Transcatheter Pacing System
Implantation with a transvenous pacemaker
Device: Transvenous Azure XT DR dual chamber pacemaker
Patients are implanted with a leadless Micra AV TPS
Patients are implanted with a transvenous Azure XT DR pacemaker
Quality of Life by SF36
Self-reported health-related quality of life as measured by Short-Form 36 quality of life questionnaire. The scale ranges from 0 to 100. 0 denotes minimal quality of life and 100 denotes maximum quality of life.
Time frame: 7 months
Patient Acceptance by FPAS
Self-reported patient acceptance as measured by Florida Patient Acceptance Scale. The scale ranges from 0-100. 0 denotes minimal device acceptance and 100 denotes maximal device acceptance.
Time frame: 7 months
Exercise capacity by 6MWT
Exercise capacity as measured by 6-minute walk test
Time frame: 7 months
Plan to share: No — In accordance with Danish and European data protection law
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for Nov 2026, 38 months after the start.
Of 44 interventional studies with no phase under Atrioventricular Block, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 38 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.